SNPHY vs. VRT
SNPHY (Santen Pharmaceutical Co) and VRT (Vertiv Holdings Co.) are both stocks. SNPHY operates in Drug Manufacturers - General (Healthcare), while VRT operates in Electrical Equipment & Parts (Industrials). Over the past 5 years, SNPHY returned -1.86%/yr vs 63.70%/yr for VRT. At a 0.07 correlation, their price movements are largely independent.
Performance
SNPHY vs. VRT - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SNPHY achieves a 19.51% return, which is significantly lower than VRT's 96.57% return.
SNPHY
- 1D
- 1.28%
- 1M
- 2.84%
- YTD
- 19.51%
- 6M
- 21.04%
- 1Y
- 5.08%
- 3Y*
- 13.29%
- 5Y*
- -1.86%
- 10Y*
- -1.06%
VRT
- 1D
- -11.07%
- 1M
- -2.77%
- YTD
- 96.57%
- 6M
- 91.55%
- 1Y
- 173.44%
- 3Y*
- 138.19%
- 5Y*
- 63.70%
- 10Y*
- —
SNPHY vs. VRT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
SNPHY Santen Pharmaceutical Co | 19.51% | 3.17% | 3.67% | 22.59% | -34.03% | -25.14% | -14.64% | 33.33% | -15.31% |
VRT Vertiv Holdings Co. | 96.57% | 42.80% | 136.82% | 251.81% | -45.25% | 33.80% | 69.36% | 12.55% | 1.03% |
Correlation
The correlation between SNPHY and VRT is 0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.09 |
Correlation (3Y) Calculated over the trailing 3-year period | -0.01 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.06 |
Correlation (All Time) Calculated using the full available price history since Jul 30, 2018 | 0.07 |
Fundamentals
SNPHY:
$4.01B
VRT:
$124.82B
SNPHY:
¥114.09
VRT:
$3.99
SNPHY:
17.44
VRT:
79.86
SNPHY:
0.19
VRT:
0.35
SNPHY:
2.24
VRT:
11.48
SNPHY:
2.17
VRT:
29.41
SNPHY:
¥295.63B
VRT:
$10.84B
SNPHY:
¥165.41B
VRT:
$3.92B
SNPHY:
¥65.30B
VRT:
$2.35B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SNPHY vs. VRT — Risk / Return Rank
SNPHY
VRT
SNPHY vs. VRT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Santen Pharmaceutical Co (SNPHY) and Vertiv Holdings Co. (VRT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SNPHY | VRT | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.80 | ||
| Sortino ratioReturn per unit of downside risk | -2.79 | ||
| Omega ratioGain probability vs. loss probability | 1.06 | 1.42 | -0.36 |
| Calmar ratioReturn relative to maximum drawdown | 0.25 | 6.89 | -6.64 |
| Martin ratioReturn relative to average drawdown | 0.50 | 18.18 | -17.68 |
Loading charts...
Drawdowns
SNPHY vs. VRT - Drawdown Comparison
The maximum SNPHY drawdown since its inception was -82.47%, which is greater than VRT's maximum drawdown of -71.24%. Use the drawdown chart below to compare losses from any high point for SNPHY and VRT.
Loading charts...
Drawdown Indicators
| SNPHY | VRT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -82.47% | -71.24% | -11.23% |
Max Drawdown (1Y)Largest decline over 1 year | -20.31% | -25.32% | +5.01% |
Max Drawdown (3Y)Largest decline over 3 years | -31.88% | -61.28% | +29.40% |
Max Drawdown (5Y)Largest decline over 5 years | -58.99% | -71.24% | +12.25% |
Max Drawdown (10Y)Largest decline over 10 years | -69.08% | — | — |
Current DrawdownCurrent decline from peak | -65.67% | -15.37% | -50.30% |
Average DrawdownAverage peak-to-trough decline | -51.30% | -16.22% | -35.08% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.23% | 9.58% | +0.65% |
Volatility
SNPHY vs. VRT - Volatility Comparison
The current volatility for Santen Pharmaceutical Co (SNPHY) is 13.49%, while Vertiv Holdings Co. (VRT) has a volatility of 20.96%. This indicates that SNPHY experiences smaller price fluctuations and is considered to be less risky than VRT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SNPHY | VRT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.49% | 20.96% | -7.47% |
Volatility (6M)Calculated over the trailing 6-month period | 33.59% | 46.74% | -13.15% |
Volatility (1Y)Calculated over the trailing 1-year period | 48.15% | 60.09% | -11.94% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 42.22% | 62.33% | -20.11% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 36.39% | 54.83% | -18.44% |
Dividends
SNPHY vs. VRT - Dividend Comparison
SNPHY has not paid dividends to shareholders, while VRT's dividend yield for the trailing twelve months is around 0.07%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
SNPHY Santen Pharmaceutical Co | 0.00% | 1.26% | 1.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.74% | 1.98% |
VRT Vertiv Holdings Co. | 0.07% | 0.11% | 0.10% | 0.05% | 0.07% | 0.04% | 0.05% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
SNPHY vs. VRT - Financials Comparison
This section allows you to compare key financial metrics between Santen Pharmaceutical Co and Vertiv Holdings Co.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
SNPHY vs. VRT - Profitability Comparison
SNPHY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Santen Pharmaceutical Co reported a gross profit of 50.58B and revenue of 82.35B. Therefore, the gross margin over that period was 61.4%.
VRT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Vertiv Holdings Co. reported a gross profit of 999.70M and revenue of 2.65B. Therefore, the gross margin over that period was 37.7%.
SNPHY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Santen Pharmaceutical Co reported an operating income of 17.39B and revenue of 82.35B, resulting in an operating margin of 21.1%.
VRT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Vertiv Holdings Co. reported an operating income of 440.10M and revenue of 2.65B, resulting in an operating margin of 16.6%.
SNPHY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Santen Pharmaceutical Co reported a net income of 15.83B and revenue of 82.35B, resulting in a net margin of 19.2%.
VRT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Vertiv Holdings Co. reported a net income of 390.10M and revenue of 2.65B, resulting in a net margin of 14.7%.
Frequently Asked Questions
SNPHY and VRT have a correlation of 0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
VRT has higher volatility (20.96%) compared to SNPHY (13.49%). In terms of maximum drawdown, SNPHY dropped -82.47% vs VRT's -71.24%.
VRT currently has the higher Sharpe Ratio (2.91 vs 0.11), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SNPHY and VRT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer